Patents by Inventor Patrick Bureau
Patrick Bureau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230295152Abstract: The present disclosure relates to compounds of formula (Ia) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling. These compounds may also be useful in treating cancer when administered in combination with at least one additional therapy.Type: ApplicationFiled: November 20, 2020Publication date: September 21, 2023Applicant: SENDA BIOSCIENCES, INC.Inventors: Alessandra BARTOLOZZI, John Robert PROUDFOOT, Timothy BRIGGS, John MANCUSO, Karunakar Reddy BONEPALLY, Patrick BUREAU, Tianlin GUO, Maxence BOS, Anna BLOIS, Bernard LANTER, Steven John TAYLOR, Leonard BUCKBINDER, Francesca BARONE
-
Publication number: 20190100534Abstract: Cephem and penem compounds having a styrylmethylene moiety at the 3-position in the cephem or penem ring to which a positively charged leaving group is bonded and wherein the leaving group contains a vicinal diol or is bonded to a unsubstituted or substituted catechol. The leaving group can be a positively charge nitrogen leaving group. Cephems include cephalosporins, cephamycins, carbacephems, and oxacephems. Penems include penems, carbapenems and oxapenems. Preferred cephems are cephalosporins. Preferred penems are carbapenems. Compounds exhibit antibiotic activity against Gram-negative bacteria and/or Gram-positive bacteria. Compounds exhibit antibiotic activity against bacteria which exhibit multi-drug resistance. Compounds of the invention exhibit antibiotic activity against bacterial strains which produce extended spectrum beta-lactamases (ESBL), which produce AmpC beta-lactamases or which produce a carbapenemase.Type: ApplicationFiled: October 4, 2018Publication date: April 4, 2019Inventors: Larry D. SUTTON, Robert ZAMBONI, Patrick BUREAU, Avid HASSANPOUR, Laura MAMANI LAPARRA, Marc VIDAL, Simon WOO, Nancy ZHOU, Richard M. KEENAN
-
Patent number: 9365614Abstract: A compound of Formula I or a salt thereof, methods for the preparation thereof, and related methods and compositions.Type: GrantFiled: May 23, 2014Date of Patent: June 14, 2016Assignee: Pharmascience Inc.Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
-
Publication number: 20140336134Abstract: A compound of Formula I or a salt thereof, methods for the preparation thereof, and related methods and compositions.Type: ApplicationFiled: May 23, 2014Publication date: November 13, 2014Applicant: Pharmascience Inc.Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
-
Patent number: 8765681Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.Type: GrantFiled: November 8, 2012Date of Patent: July 1, 2014Assignee: Pharmascience Inc.Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
-
Patent number: 8648094Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.Type: GrantFiled: March 21, 2012Date of Patent: February 11, 2014Assignee: Pharmascience, Inc.Inventors: Alain Laurent, Scott Jarvis, Patrick Bureau, Alain Boudreault, James Jaquith
-
Patent number: 8575113Abstract: The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds are useful in treating proliferative disorders such as cancer.Type: GrantFiled: June 28, 2010Date of Patent: November 5, 2013Assignee: Pharmascience Inc.Inventors: Scott Jarvis, Alain Boudreault, Patrick Bureau, James B. Jaquith, Alain Laurent, Delphine Labit
-
Patent number: 8395449Abstract: The present invention relates to a power supply control network of an amplifying active elements system enabling at least one control signal to be transmitted to N different control systems of the power supply voltage of P different composed active amplifying elements. It comprises a set of distributor elements of power supply control signals connected in cascade.Type: GrantFiled: October 2, 2009Date of Patent: March 12, 2013Assignee: PL Technologies AGInventors: Christian Outin, Patrick Bureau, Jérôme David, Thierry Parquet, Didler Martineau
-
Publication number: 20120195915Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.Type: ApplicationFiled: March 21, 2012Publication date: August 2, 2012Applicant: PHARMASCIENCE INC.Inventors: Alain Laurent, Scott Jarvis, Patrick Bureau, Alain Boudreault, James Jaquith
-
Patent number: 8163792Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.Type: GrantFiled: May 16, 2007Date of Patent: April 24, 2012Assignee: Pharmascience Inc.Inventors: Alain Laurent, Scott Jarvis, Patrick Bureau, Alain Boudreault, James Jaquith
-
Patent number: 8063095Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.Type: GrantFiled: December 4, 2006Date of Patent: November 22, 2011Assignee: Pharmascience Inc.Inventors: Alain Laurent, Kim Hewitt, Stephen Morris, Patrick Bureau, Alain Boudreault, Scott Jarvis, James Jaquith
-
Publication number: 20110175679Abstract: The present invention relates to a power supply control network of an amplifying active elements system enabling at least one control signal to be transmitted to N different control systems of the power supply voltage of P different composed active amplifying elements. It comprises a set of distributor elements of power supply control signals connected in cascade.Type: ApplicationFiled: October 2, 2009Publication date: July 21, 2011Inventors: Christian Outin, Patrick Bureau, Jérôme David, Thierry Parquet, Didler Martineau
-
Publication number: 20100292269Abstract: The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains.Type: ApplicationFiled: June 28, 2010Publication date: November 18, 2010Applicant: AEGERA THERAPEUTICS, INC.Inventors: Scott Jarvis, Alain Boudreault, Patrick Bureau, James Jaquith, Alain Laurent, Delphine Labit
-
Patent number: 7795298Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.Type: GrantFiled: December 4, 2006Date of Patent: September 14, 2010Assignee: Aegera Therapeutics, Inc.Inventors: Alain Laurent, Kim Hewitt, Stephen Morris, Patrick Bureau, Alain Boudreault, Scott Jarvis, James Jaquith
-
Publication number: 20100221261Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.Type: ApplicationFiled: November 17, 2009Publication date: September 2, 2010Applicant: Aegera Therapeutics, Inc.Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
-
Publication number: 20100203012Abstract: Disclosed herein is a compound of Formula 1: or a salt thereof, in which R1, R1a, R100, R100a, R2, R200, R3, R300, A, A1, Q, Q1 and BG are as defined herein. Also disclosed is the use of the compounds of Formula 1 to treat disorders of dysregulated apoptosis, such as cancer and cellular proliferative disorders.Type: ApplicationFiled: May 30, 2008Publication date: August 12, 2010Applicant: Aegera Therapeutics, Inc.Inventors: Alain Laurent, Patrick Bureau, James Jaquith, John Gillard, Yannick Rose
-
Patent number: 7772177Abstract: The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds are useful in treating proliferative disorders such as cancer.Type: GrantFiled: May 16, 2006Date of Patent: August 10, 2010Assignee: Aegera Therapeutics, Inc.Inventors: Scott Jarvis, Alain Boudreault, Patrick Bureau, James Jaquith, Alain Laurent, Delphine Labit
-
Patent number: 7697616Abstract: A method of modulating a digital signal of width L in frequency on a given useful frequency band is described The digital signal is separated into N blocks bn (1?n?N). The given useful frequency band is split into N contiguous parts Pn. Channels Cn, of width 1n in frequency, lying within an associated part Pn, are defined. The channels Cn are separated, a distributing of each block of digital signals bn over the associated channel Cn.Type: GrantFiled: December 15, 2003Date of Patent: April 13, 2010Assignee: ThalesInventors: Bruno Le Breton, Pierre Vasseur, Patrick Bureau
-
Patent number: 7645741Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.Type: GrantFiled: November 1, 2007Date of Patent: January 12, 2010Assignee: Aegera Therapeutics, Inc.Inventors: Alain Boudreault, James B. Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
-
Patent number: D775328Type: GrantFiled: December 2, 2013Date of Patent: December 27, 2016Assignee: BCE PHARMA INC.Inventors: Patrick Bureau, Francois Cauchon, Francois Morin